Active substance
Vasopressin
- SFDA 3
- US FDA 18
- Health Canada 2
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Vasopressin BOS | 20 U/ml | Solution for infusion · Intravenous use | 10 Vial | SAR 1389.80 | Generic · Prescription | Boston Oncology Arabia | Valid |
| Vatowis | 20 U/ml | Injection · Intravenous use | 20 Vial | SAR 2421.20 | Generic · Prescription | Eugia Pharma Specialities Limited | Valid |
| Progecta | 20 IU/ml | Solution for injection · Intrathecal, Intravenous, Intramuscular | 10 Ampoule | SAR 1489.05 | NCE · Prescription | JSC FARMAK | Suspended · Not Marketed |
Indications — CHI Daman Drug Formulary
Septic Shock
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VASOSTRICT | 20UNITS/ML (20UNITS/ML); 200UNITS/10ML (20UNITS/ML); 40UNITS/100ML (0.4UNITS/ML); 20UNITS/100ML (0.2UNITS/ML) | solution · intravenous | PH HEALTH | Prescription | 17 Apr 2014 |
| VASOPRESSIN | 20UNITS/ML (20UNITS/ML); 200UNITS/10ML (20UNITS/ML) | solution · intravenous | AM REGENT | Prescription | 3 Aug 2020 |
| VASOPRESSIN | 20UNITS/ML (20UNITS/ML) | solution · intravenous | AMPHASTAR PHARMS INC | Prescription | 18 Jul 2022 |
| VASOPRESSIN | 20UNITS/ML (20UNITS/ML) | solution · intravenous | AMNEAL | Prescription | 5 Aug 2022 |
| VASOPRESSIN | 20UNITS/ML (20UNITS/ML) | solution · intravenous | EUGIA PHARMA | Prescription | 15 Aug 2022 |
| VASOPRESSIN | 20UNITS/ML (20UNITS/ML) | solution · intravenous | FRESENIUS KABI USA | Prescription | 26 May 2023 |
| VASOPRESSIN IN SODIUM CHLORIDE 0.9% | 20UNITS/100ML (0.2UNITS/ML); 40UNITS/100ML (0.4UNITS/ML) | solution · intravenous | BAXTER HLTHCARE CORP | Prescription | 29 Sep 2023 |
| VASOPRESSIN | 20UNITS/100ML (0.2UNITS/ML) | solution · intravenous | CIPLA | Prescription | 6 Dec 2023 |
| VASOPRESSIN | 20UNITS/ML (20UNITS/ML) | solution · intravenous | GLAND | Prescription | 9 Feb 2024 |
| VASOPRESSIN IN DEXTROSE 5% | 40UNITS/100ML (0.4UNITS/ML) | solution · intravenous | GLAND | Prescription | 9 Feb 2024 |
| VASOPRESSIN | 20UNITS/ML (20UNITS/ML) | solution · intravenous | DR REDDYS | Prescription | 8 May 2024 |
| VASOPRESSIN IN DEXTROSE 5% | 40UNITS/100ML (0.4UNITS/ML) | solution · intravenous | DR REDDYS | Prescription | 8 May 2024 |
| VASOPRESSIN IN SODIUM CHLORIDE 0.9% | 20UNITS/100ML (0.2UNITS/ML); 40UNITS/100ML (0.4UNITS/ML) | solution · intravenous | LONG GROVE PHARMS | Prescription | 11 Jul 2024 |
| VASOPRESSIN | 20UNITS/ML (20UNITS/ML) | solution · intravenous | SANDOZ | Prescription | 6 May 2026 |
| VASOPRESSIN | 200UNITS/10ML (20UNITS/ML) | solution · intravenous | SANDOZ | Prescription | 6 May 2026 |
| VASOSTRICT | 60UNITS/100ML (0.6UNITS/ML); 50UNITS/50ML (1UNITS/ML) | solution · intravenous | PH HEALTH | Discontinued | 17 Apr 2014 |
| VASOPRESSIN | 20UNITS/ML (20UNITS/ML) | solution · intravenous | EAGLE PHARMS | Discontinued | 15 Dec 2021 |
| VASOPRESSIN IN SODIUM CHLORIDE 0.9% | 50UNITS/50ML (1UNIT/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution · intravenous | LONG GROVE PHARMS | Discontinued | 11 Jul 2024 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| VASOPRESSIN INJECTION USP | 02247938 | 20 UNIT / ML | SOLUTION · SUBCUTANEOUS; INTRAMUSCULAR | SANDOZ CANADA INCORPORATED |
| VASOPRESSIN INJECTION, USP | 02139502 | 20 UNIT / ML | SOLUTION · INTRAMUSCULAR; SUBCUTANEOUS | FRESENIUS KABI CANADA LTD |
Safety signals and safety-related labeling changes
- US FDA 26 Mar 2021 VASOSTRICT — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.